Rhythm Pharmaceuticals (RYTM) to Release Quarterly Earnings on Thursday

Rhythm Pharmaceuticals (NASDAQ:RYTM) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Rhythm Pharmaceuticals to post earnings of ($0.80) per share and revenue of $56.1550 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Rhythm Pharmaceuticals Trading Down 3.4%

Shares of RYTM stock opened at $96.35 on Tuesday. The company’s fifty day moving average price is $105.09 and its 200-day moving average price is $103.52. The stock has a market cap of $6.43 billion, a PE ratio of -31.08 and a beta of 2.00. Rhythm Pharmaceuticals has a 12 month low of $45.90 and a 12 month high of $122.20.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Wells Fargo & Company lifted their price objective on Rhythm Pharmaceuticals from $129.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Zacks Research upgraded shares of Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th. Citigroup reissued an “outperform” rating on shares of Rhythm Pharmaceuticals in a report on Friday, December 12th. Wall Street Zen downgraded shares of Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $131.50.

Insider Transactions at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, insider Pamela J. Cramer sold 3,350 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $111.00, for a total transaction of $371,850.00. Following the transaction, the insider owned 20,814 shares of the company’s stock, valued at $2,310,354. The trade was a 13.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Hunter C. Smith sold 4,385 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total transaction of $444,025.10. Following the completion of the sale, the chief financial officer directly owned 110,512 shares of the company’s stock, valued at approximately $11,190,445.12. This trade represents a 3.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 25,003 shares of company stock valued at $2,589,015. Company insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Invesco Ltd. grew its stake in shares of Rhythm Pharmaceuticals by 102.8% in the 4th quarter. Invesco Ltd. now owns 291,150 shares of the company’s stock worth $31,165,000 after buying an additional 147,595 shares in the last quarter. Empowered Funds LLC lifted its holdings in shares of Rhythm Pharmaceuticals by 94.1% in the 4th quarter. Empowered Funds LLC now owns 4,164 shares of the company’s stock valued at $446,000 after acquiring an additional 2,019 shares during the last quarter. XTX Topco Ltd purchased a new position in Rhythm Pharmaceuticals in the fourth quarter worth about $1,117,000. Wellington Management Group LLP increased its stake in Rhythm Pharmaceuticals by 922.0% during the fourth quarter. Wellington Management Group LLP now owns 250,156 shares of the company’s stock worth $26,777,000 after acquiring an additional 225,679 shares during the last quarter. Finally, SummitTX Capital L.P. raised its position in Rhythm Pharmaceuticals by 580.2% during the fourth quarter. SummitTX Capital L.P. now owns 80,729 shares of the company’s stock valued at $8,641,000 after purchasing an additional 68,860 shares during the period.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.